Skip to main content

Advertisement

SpringerLink
Log in

Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome

  • Antiphospholipid Syndrome (S Zuily, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Thrombotic manifestations of antiphospholipid syndrome (APS) are well known, and various non-stroke neuro-psychiatric manifestations (NPMs) have also been consistently described, but their place in APS remains unclear. Some syndromes, such as migraine or cognitive dysfunction, are frequently described in APS, whereas others, like seizure, multiple sclerosis-like symptoms, transverse myelitis, movement disorders, or psychiatric symptoms, are rarely found. Overlap with other autoimmune diseases, in particular with systemic lupus erythematosus, the lack of large sample size prospective studies, and discrepancies in antiphospholipid antibody (aPL) determinations complicate the study of the relationship between those disorders and aPL/APS. This review article aimed to summarize updated data on pathophysiologic, epidemiologic, and radiologic findings about non-stroke NPM described in primary APS and aPL-positive patients without overlap of other autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet Lond Engl. 1983;2(8361):1211–4.

    Article  CAS  Google Scholar 

  2. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11.

    Article  CAS  PubMed  Google Scholar 

  3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH. 2006;4(2):295–306.

    Article  CAS  PubMed  Google Scholar 

  4. Kent M, Alvarez F, Vogt E, Fyffe R, Ng AK, Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol. 1997;24(9):1725–33.

    CAS  PubMed  Google Scholar 

  5. Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci. 1998;156(2):211–9.

    Article  CAS  PubMed  Google Scholar 

  6. Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003;12(6):436–42.

    Article  CAS  PubMed  Google Scholar 

  7. Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. Last report of international experts’ conference, which summarizes experts’ conclusions on clinical non-criteria manifestations of APS and their place in the classification criteria.

    Article  PubMed  Google Scholar 

  8. Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21(2):251–64.

    Article  CAS  PubMed  Google Scholar 

  9. Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus. 2010;19(5):613–9.

    Article  CAS  PubMed  Google Scholar 

  10. Kozora E, Erkan D, Zhang L, Zimmerman R, Ramon G, Ulug AM, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exp Rheumatol. 2014;32(1):34–40. Proof of aPL implication in cognitive dysfunction independently of overlap with lupus.

    PubMed  Google Scholar 

  11. Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166(20):2278–84.

    Article  PubMed  Google Scholar 

  12. Coín MA, Vilar-López R, Peralta-Ramírez I, Hidalgo-Ruzzante N, Callejas-Rubio JL, Ortego-Centeno N, et al. The role of antiphospholipid autoantibodies in the cognitive deficits of patients with systemic lupus erythematosus. Lupus. 2015;24(8):875–9. Recent paper with good methodology to evaluate the association between aPL and cognitive dysfunction.

    Article  PubMed  Google Scholar 

  13. Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64(10):1490–3.

  14. Gómez-Puerta JA, Martín H, Amigo M-C, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.

    Article  Google Scholar 

  15. De Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012;2012:981519.

    PubMed  PubMed Central  Google Scholar 

  16. Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology. 2005;210(10):749–54.

  17. Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172–5.

  18. Appenzeller S, Yeh S, Maruyama M, Barros SM, de Carvalho JF. Chorea in primary antiphospholipid syndrome is associated with rheumatic fever. Rheumatol Int. 2012;32(9):2857–61.

    Article  PubMed  Google Scholar 

  19. Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.

    Article  PubMed  Google Scholar 

  20. Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, et al. Transverse myelitis in patients with antiphospholipid antibodies—the importance of early diagnosis and treatment. Clin Rheumatol. 2002;21(3):207–10.

    Article  CAS  PubMed  Google Scholar 

  21. Chapman J, Abu-Katash M, Inzelberg R, Yust I, Neufeld MY, Vardinon N, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci. 2002;15(203–204):81–4.

    Article  Google Scholar 

  22. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc JINS. 1997;3(4):377–86.

    CAS  PubMed  Google Scholar 

  23. Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol. 2002;24(4):527–33.

    Article  PubMed  Google Scholar 

  24. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42(4):735–41.

    Article  CAS  PubMed  Google Scholar 

  25. Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, et al. Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS ONE. 2012;7(3):e33824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus. 1995;4(6):482–5.

    Article  CAS  PubMed  Google Scholar 

  27. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11(1):36–8.

    Article  CAS  PubMed  Google Scholar 

  28. Hughes GRV. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J. 2003;79(928):81–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Iñiguez C, Pascual C, Pardo A, Martinez-Castrillo JC, Alvarez-Cermeño JC. Antiphospholipid antibodies in migraine. Headache. 1991;31(10):666–8.

    Article  PubMed  Google Scholar 

  30. Cavestro C, Micca G, Molinari F, Bazzan M, DI Pietrantonj C, Aloi R, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost JTH. 2011;9(7):1350–4.

    Article  CAS  PubMed  Google Scholar 

  31. Rajan R, Ahluwalia J, Lal V. Prothrombotic states in migraine. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2014;20(8):851–6.

    Article  CAS  Google Scholar 

  32. Hering R, Couturier EG, Steiner TJ, Asherson RA, Clifford RF. Anticardiolipin antibodies in migraine. Cephalalgia Int J Headache. 1991;11(1):19–21.

    Article  CAS  Google Scholar 

  33. Williams FMK, Cherkas LF, Bertolaccini ML, Murru V, Surdulescu GL, Hughes GRV, et al. Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins. Cephalalgia Int J Headache. 2008;28(10):1048–52.

    Article  CAS  Google Scholar 

  34. Tsakiris DA, Kappos L, Reber G, Marbet GA, Le Floch-Rohr J, Roux E, et al. Lack of association between antiphospholipid antibodies and migraine. Thromb Haemost. 1993;69(5):415–7.

    CAS  PubMed  Google Scholar 

  35. Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology. 1998;50(5):1433–40.

    Article  CAS  PubMed  Google Scholar 

  36. Intiso D, Crociani P, Fogli D, Grandone E, Cappucci G, Di Rienzo F, et al. Occurrence of factor V Leiden mutation (Arg506Gln) and anticardiolipin antibodies in migraine patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2002;22(6):455–8.

    CAS  Google Scholar 

  37. Cuadrado MJ, Khamashta MA, Hughes GR. Migraine and stroke in young women. QJM Mon J Assoc Physicians. 2000;93(5):317–8.

    Article  CAS  Google Scholar 

  38. Stojanovich L, Kontic M, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. Clin Exp Rheumatol. 2013;31(5):756–60.

    PubMed  Google Scholar 

  39. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–8. Provide strong epidemiologic data from the largest prospective cohort of APS patients.

    Article  CAS  PubMed  Google Scholar 

  40. Francès C, Niang S, Laffitte E, le Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52(6):1785–93.

    Article  PubMed  Google Scholar 

  41. Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol. 2005;23(4):499–504.

    CAS  PubMed  Google Scholar 

  42. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31(7):1344–8.

    PubMed  Google Scholar 

  43. Liimatainen S, Peltola M, Fallah M, Kharazmi E, Haapala A-M, Peltola J. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur J Neurol Off J Eur Fed Neurol Soc. 2009;16(1):134–41.

    CAS  Google Scholar 

  44. Maalouf NN, Hinduja A, Shihabuddin BS. Primary antiphospholipid syndrome manifesting as partial status epilepticus. Neurosci Riyadh Saudi Arab. 2013;18(2):160–2.

    Google Scholar 

  45. Ong M-S, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014;71(5):569–74. First study to properly assess the link between APS diagnosis and epilepsy in a large study-population cohort.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000;79(1):57–68.

    Article  CAS  Google Scholar 

  47. Ahbeddou N, Ait Ben Haddou E, Hammi S, Slimani C, Regragui W, Benomar A, et al. Multiple sclerosis associated with antiphospholipid syndrome: diagnostic and therapeutic difficulties. Rev Neurol (Paris). 2012;168(1):65–9.

    Article  CAS  Google Scholar 

  48. Lima I, Melo A, Brandi IV, Costa O, Santiago M. Lupoid sclerosis: what is the role of antiphospholipid antibodies? J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2007;13(2):85–6.

    Google Scholar 

  49. Komolafe MA, Komolafe EO, Sunmonu TA, Olateju SO, Asaleye CM, Adesina OA, et al. New onset neuromyelitis optica in a young Nigerian woman with possible antiphospholipid syndrome: a case report. J Med Case Reports. 2008;2:348.

    Article  PubMed Central  Google Scholar 

  50. Fernández-Fernández FJ, Rivera-Gallego A, de la Fuente-Aguado J, Pérez-Fernández S, Muñoz-Fernández D. Antiphospholipid syndrome mimicking multiple sclerosis in two patients. Eur J Intern Med. 2006;17(7):500–2.

    Article  PubMed  CAS  Google Scholar 

  51. Liedorp M, Sanchez E, van Hoogstraten IMW, von Blomberg BME, Barkhof F, Polman CH, et al. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg Psychiatry. 2007;78(10):1146–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7:36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Vilisaar J, Wilson M, Niepel G, Blumhardt LD, Constantinescu CS. A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2005;11(4):378–80.

    Article  CAS  Google Scholar 

  54. Sastre-Garriga J, Reverter JC, Font J, Tintoré M, Espinosa G, Montalban X. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol. 2001;49(3):408–11.

    Article  CAS  PubMed  Google Scholar 

  55. Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun. 2000;14(3):259–65.

    Article  CAS  PubMed  Google Scholar 

  56. IJdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 1999;8(2):109–15.

    Article  CAS  PubMed  Google Scholar 

  57. Cordoliani MA, Michon-Pasturel U, Rerat K, Arvieux J, Masy E, Hachulla E, et al. Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne. 1998;19(9):635–9.

    Article  CAS  Google Scholar 

  58. Sugiyama Y, Yamamoto T. Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J Exp Med. 1996;178(3):203–15.

    Article  CAS  PubMed  Google Scholar 

  59. Fukazawa T, Moriwaka F, Mukai M, Hamada T, Koike T, Tashiro K. Anticardiolipin antibodies in Japanese patients with multiple sclerosis. Acta Neurol Scand. 1993;88(3):184–9.

    Article  CAS  PubMed  Google Scholar 

  60. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629–34.

    Article  CAS  PubMed  Google Scholar 

  61. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol. 1998;55(4):517–21.

    Article  CAS  PubMed  Google Scholar 

  62. Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, Tournier-Lasserve E, et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry. 2002;72(5):647–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172–5.

    PubMed  PubMed Central  Google Scholar 

  64. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–24.

    Article  CAS  Google Scholar 

  65. Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody-associated chorea. J Rheumatol. 2008;35(11):2165–70.

    Article  PubMed  Google Scholar 

  66. Reiner P, Galanaud D, Leroux G, Vidailhet M, Haroche J, Huong DLT, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord Off J Mov Disord Soc. 2011;26(13):2422–7.

    Article  Google Scholar 

  67. Huang Y-C, Lyu R-K, Chen S-T, Chu Y-C, Wu Y-R. Parkinsonism in a patient with antiphospholipid syndrome—case report and literature review. J Neurol Sci. 2008;267(1–2):166–9.

    Article  PubMed  Google Scholar 

  68. Carecchio M, Comi C, Varrasi C, Stecco A, Sainaghi PP, Bhatia K, et al. Complex movement disorders in primary antiphospholipid syndrome: a case report. J Neurol Sci. 2009;281(1–2):101–3.

    Article  PubMed  Google Scholar 

  69. Chen W-H, Chen C-H, Chui C, Lui C-C, Chen C-J, Yin H-L. Antiphospholipid antibodies and cerebellar ataxia: a clinical analysis and literature review. Neuroimmunomodulation. 2014;21(6):283–90. Interesting recent review, up to date on cerebellar ataxia in aPL and APS patients.

    Article  CAS  PubMed  Google Scholar 

  70. Ishikawa N, Kobayashi M. Recurrent acute cerebellar ataxia associated with anti-cardiolipin antibodies. Brain Dev. 2010;32(7):588–91.

    Article  PubMed  Google Scholar 

  71. Sokol DK, O’Brien RS, Wagenknecht DR, Rao T, McIntyre JA. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol. 2007;190(1–2):151–6.

    Article  CAS  PubMed  Google Scholar 

  72. Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59(1):20–3.

    Article  CAS  PubMed  Google Scholar 

  73. Schwartz M, Silver H. Lymphocytes, autoantibodies and psychosis—coincidence versus etiological factor: an update. Isr J Psychiatry Relat Sci. 2000;37(1):32–6.

    CAS  PubMed  Google Scholar 

  74. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006;27(2):71–80.

    Article  CAS  PubMed  Google Scholar 

  75. Chengappa KN, Carpenter AB, Keshavan MS, Yang ZW, Kelly RH, Rabin BS, et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry. 1991;30(7):731–5.

    Article  CAS  PubMed  Google Scholar 

  76. Maes M, Meltzer H, Jacobs J, Suy E, Calabrese J, Minner B, et al. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatr Scand. 1993;87(3):160–6.

    Article  CAS  PubMed  Google Scholar 

  77. Raza H, Epstein SA, Pao M, Rosenstein DL. Mania: psychiatric manifestations of the antiphospholipid syndrome. Psychosomatics. 2008;49(5):438–41.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Barros S, de Carvalho J. Pathological gambling and primary antiphospholipid (Hughes) syndrome: a unique neuropsychiatric association. Lupus. 2011;20(10):1086–9.

    Article  PubMed  Google Scholar 

  79. Avari JN, Young RC. A patient with bipolar disorder and antiphospholipid syndrome. J Geriatr Psychiatry Neurol. 2012;25(1):26–8.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus. 2002;11(11):736–43.

    Article  CAS  PubMed  Google Scholar 

  81. Katzav A, Shoenfeld Y, Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2010;38(2–3):196–200.

    Article  CAS  PubMed  Google Scholar 

  82. Appenzeller S, Lapa AT, de Carvalho JF, Peres FA, Shoenfeld Y. Cognitive dysfunction and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14(1):95–8.

    Article  CAS  PubMed  Google Scholar 

  83. Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10(7):496–9.

    Article  CAS  PubMed  Google Scholar 

  84. Frauenknecht K, Katzav A, Weiss Lavi R, Sabag A, Otten S, Chapman J, et al. Mice with experimental antiphospholipid syndrome display hippocampal dysfunction and a reduction of dendritic complexity in hippocampal CA1 neurones. Neuropathol Appl Neurobiol. 2015;41(5):657–71. Interesting and recent bench paper, which provide structural basis for the behavioral and cognitive abnormalities of APS mice model.

    Article  CAS  PubMed  Google Scholar 

  85. Katzav A, Ben-Ziv T, Blank M, Pick CG, Shoenfeld Y, Chapman J. Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol. 2014;272(1–2):10–5.

    Article  CAS  PubMed  Google Scholar 

  86. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest. 1997;100(3):613–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Nowacki P, Ronin-Walknowska E, Ossowicka-Stepińska J. Neuropathological changes within the brain of rabbits with experimental model of antiphospholipid syndrome in different time after immunization. Folia Neuropathol Assoc Pol Neuropathol Med Res Cent Pol Acad Sci. 1999;37(4):269–72.

    CAS  Google Scholar 

  88. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8(2):127–33.

    Article  CAS  PubMed  Google Scholar 

  89. Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol. 2005;12(3):175–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15(4):191–7.

    Article  CAS  PubMed  Google Scholar 

  91. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci. 1994;54(15):1119–25.

    Article  CAS  PubMed  Google Scholar 

  92. Carter D, Olchovsky D, Yonath H, Langevitz P, Ezra D. Simultaneous deep vein thrombosis and transverse myelitis with negative serology as a first sign of antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol. 2006;25(5):756–8.

    Article  PubMed  Google Scholar 

  93. Erkan D, Kozora E, Lockshin MD. Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. Pathophysiol Off J Int Soc Pathophysiol ISP. 2011;18(1):93–102.

    CAS  Google Scholar 

  94. Zhu D-S, Fu J, Zhang Y, Li S-X, Zhang G-X, Guan Y-T, et al. Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics. J Neurol Sci. 2014;346(1–2):138–44. Good recent review on neurologic imaging in APS.

    Article  CAS  PubMed  Google Scholar 

  95. Lampropoulos CE, Koutroumanidis M, Reynolds PPM, Manidakis I, Hughes GRV, D’Cruz DP. Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005;52(3):841–6.

    Article  PubMed  Google Scholar 

  96. Pereira FR, Macri F, Jackowski MP, Kostis WJ, Gris J-C, Beregi J-P, et al. Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms. Eur Radiol. 2015.

  97. Cuadrado MJ, Khamashta MA, Hughes GR. Sticky blood and headache. Lupus. 2001;10(6):392–3.

    Article  CAS  PubMed  Google Scholar 

  98. Asherson RA, Giampaulo D, Singh S, Sulman L. Dramatic response of severe headaches to anticoagulation in a patient with antiphospholipid syndrome. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2007;13(3):173–4.

    CAS  Google Scholar 

  99. Roie EV, Labarque V, Renard M, Van Geet C, Gabriëls L. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med. 2013;75(3):326–30.

    Article  PubMed  CAS  Google Scholar 

  100. Lai J-Y, Wu P-C, Chen H-C, Lee M-B. Early neuropsychiatric involvement in antiphospholipid syndrome. Gen Hosp Psychiatry. 2012;34(5):579.e1–3.

    Article  PubMed  Google Scholar 

  101. Ayalew Y, Khattak F. Antiphospholipid antibody syndrome presenting with hemichorea. Case Rep Rheumatol. 2012;2012:471543.

    PubMed  PubMed Central  Google Scholar 

  102. Safarpour D, Buckingham S, Jabbari B. Chorea associated with high titers of antiphospholipid antibodies in the absence of antiphospholipid antibody syndrome. Tremor Hyperkinetic Mov N Y N. 2015;5:294.

    Google Scholar 

  103. Demonty J, Gonce M, Ribai P, Verellen-Dumoulin C, Hustinx R. Chorea associated with anti-phospholipid antibodies: case report. Acta Clin Belg. 2010;65(5):350–3.

    Article  CAS  PubMed  Google Scholar 

  104. Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23(14):1449–51.

    Article  CAS  PubMed  Google Scholar 

  105. Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73(6):1176–80. Only therapeutic trial to evaluate the benefit of an immunosuppressive drug in non-criteria APS manifestations.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department, UFR Medicine, University of Lille, Lille, France

    Cécile M. Yelnik

  2. Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA

    Cécile M. Yelnik & Elizabeth Kozora

  3. Department of Medicine, National Jewish Health, Denver, CO, USA

    Elizabeth Kozora

  4. Departments of Psychiatry and Neurology, University of Colorado School of Medicine, Aurora, CO, USA

    Elizabeth Kozora

  5. Department of Medicine, Faculty of Medical Science, State University of Campinas, Campinas, Brazil

    Simone Appenzeller

Authors
  1. Cécile M. Yelnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth Kozora
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simone Appenzeller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cécile M. Yelnik.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

This article is part of the Topical Collection on Antiphospholipid Syndrome

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yelnik, C.M., Kozora, E. & Appenzeller, S. Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep 18, 11 (2016). https://doi.org/10.1007/s11926-016-0568-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0568-x

Keywords

Search

Navigation